[go: up one dir, main page]

BR0307871A - Proteìnas contendo domìnio de folistatina - Google Patents

Proteìnas contendo domìnio de folistatina

Info

Publication number
BR0307871A
BR0307871A BR0307871-0A BR0307871A BR0307871A BR 0307871 A BR0307871 A BR 0307871A BR 0307871 A BR0307871 A BR 0307871A BR 0307871 A BR0307871 A BR 0307871A
Authority
BR
Brazil
Prior art keywords
domain
folistatin
proteins
disorders
gdf
Prior art date
Application number
BR0307871-0A
Other languages
English (en)
Inventor
Jennifer J Hill
Neil M Wolfman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0307871A publication Critical patent/BR0307871A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"PROTEìNAS CONTENDO DOMìNIO DE FOLISTATINA". A presente invenção refere-se ao uso de proteínas compreendendo pelo menos um domínio de folistatina para modular o nível ou a atividade de fator-8 de diferenciação e crescimento (GDF-8). Mais particularmente, a invenção refere-se ao uso de proteínas compreendendo pelo menos um domínio de folistatina, excluindo a própria folistatina, para tratar distúrbios que são relacionadas à modulação do nível ou atividade de GDF-8. A invenção é útil para tratar distúrbios e doenças, particularmente aquelas em que um aumento de tecido muscular seria terapeuticamente benéfico. A invenção é também útil para tratar doenças e distúrbios relacionados com metabolismo, tecido adiposo e degeneração de osso.
BR0307871-0A 2002-02-21 2003-02-21 Proteìnas contendo domìnio de folistatina BR0307871A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35784602P 2002-02-21 2002-02-21
US43464502P 2002-12-20 2002-12-20
PCT/US2003/005150 WO2003072714A2 (en) 2002-02-21 2003-02-21 Follistatin domain containing proteins

Publications (1)

Publication Number Publication Date
BR0307871A true BR0307871A (pt) 2005-04-12

Family

ID=27767537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307871-0A BR0307871A (pt) 2002-02-21 2003-02-21 Proteìnas contendo domìnio de folistatina

Country Status (11)

Country Link
US (3) US7572763B2 (pt)
EP (1) EP1572934A4 (pt)
JP (2) JP4429728B2 (pt)
KR (1) KR20040096592A (pt)
AU (1) AU2003216345A1 (pt)
BR (1) BR0307871A (pt)
CA (1) CA2476654A1 (pt)
MX (1) MXPA04008149A (pt)
NO (1) NO20043564L (pt)
PL (1) PL374966A1 (pt)
WO (1) WO2003072714A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003072715A2 (en) * 2002-02-21 2003-09-04 Wyeth Gasp1: a follistatin domain containing protein
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
WO2004024092A2 (en) * 2002-09-16 2004-03-25 Wyeth Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
JP5568208B2 (ja) * 2003-01-14 2014-08-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌治療感作物質
MXPA05012965A (es) 2003-06-02 2006-03-09 Wyeth Corp Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello.
WO2005005471A2 (en) * 2003-07-11 2005-01-20 Develogen Aktiengesellschaft Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
AU2005219441A1 (en) * 2004-03-02 2005-09-15 Acceleron Pharma Inc. ALK7 and myostatin inhibitors and uses thereof
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
US9045553B2 (en) 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
US7316998B2 (en) 2004-05-27 2008-01-08 Acceleron Pharma Inc. Cerberus/Coco derivatives and uses thereof
US20060034831A1 (en) * 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
CA2601667A1 (en) * 2005-03-23 2006-09-28 Wyeth Detection of gdf-8 modulating agents
JP2008537777A (ja) * 2005-03-23 2008-09-25 ワイス Ｇｄｆ−８調節剤に対する免疫応答の検出
PT1915397E (pt) 2005-08-19 2015-04-30 Univ Pennsylvania Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
AU2007230604A1 (en) * 2006-03-28 2007-10-04 Wyeth GDF-9/BMP-15 modulators for the treatment of bone disorders
JP2010512326A (ja) 2006-12-08 2010-04-22 アクセルロン ファーマ， インコーポレイテッド Ｃｅｒｂｅｒｕｓ、Ｃｏｃｏおよびこれらの誘導体の使用
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2315602A4 (en) 2008-06-26 2011-11-02 Acceleron Pharma Inc METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
KR20140077977A (ko) 2011-10-21 2014-06-24 화이자 인코포레이티드 철을 첨가하여 세포 배양을 개선하는 방법
US20180193306A1 (en) 2012-03-23 2018-07-12 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders and bone disorders
SG11201408042YA (en) 2012-06-15 2015-01-29 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
CA2880649C (en) 2012-08-01 2023-03-14 Elizabeth MCNALLY Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
IL290653B1 (en) * 2012-10-24 2025-01-01 Celgene Corp Biomarker for use in the treatment of anemia
NZ747350A (en) 2012-10-24 2020-07-31 Celgene Corp Methods for treating anemia
EP3964224A1 (en) 2012-11-02 2022-03-09 Celgene Corporation Activin-actrii antagonists and uses for use in treating renal disease
CN104902915B (zh) 2013-01-25 2018-07-06 夏尔人类遗传性治疗公司 治疗杜兴氏肌营养不良的卵泡抑素
JP2014151438A (ja) * 2013-02-04 2014-08-25 Koito Mfg Co Ltd レーザー溶着方法
GB201308117D0 (en) * 2013-05-06 2013-06-12 Univ Leuven Kath Inhibitor of calcifying disorders
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
BR112016028520A2 (pt) 2014-06-04 2017-10-24 Acceleron Pharma Inc métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina
KR20170129233A (ko) 2015-03-26 2017-11-24 악셀레론 파마 인코포레이티드 폴리스타틴-관련된 융합 단백질 및 이들의 용도
SMT202400299T1 (it) 2016-07-27 2024-09-16 Acceleron Pharma Inc Composizioni per l'uso nel trattamento della mielofibrosi
WO2018218273A1 (en) * 2017-05-29 2018-12-06 Paranta Biosciences Limited Method of treating hypertension and kidney disease
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
BR112020016923A2 (pt) * 2018-02-20 2020-12-15 Epirium Bio Inc. Método para reverter ou atenuar lesão, ou fraqueza ou perda óssea, ou para evitar fraturas em um indivíduo, e, composição
CA3124415A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
MX2019015589A (es) * 2019-12-19 2021-06-21 Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular.

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5116944A (en) 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6673534B1 (en) * 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
EP1378572B1 (en) * 1993-05-12 2006-10-25 Genetics Institute, LLC Bmp-11 compositions
AU677866B2 (en) * 1993-08-26 1997-05-08 Board Of Trustees Of The University Of Illinois, The Neural regeneration using human bone morphogenetic proteins
US7332575B2 (en) * 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
DK0776337T3 (da) * 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8921698A (en) * 1997-08-29 1999-03-16 Human Genome Sciences, Inc. Follistatin-3
WO1999024057A2 (en) 1997-11-07 1999-05-20 Genetics Inst Neuronal uses of bmp-11
US5942420A (en) * 1997-11-17 1999-08-24 Millennium Biotherapeutics, Inc. Molecules of the follistatin-related protein family and uses therefor
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
EP1075272B1 (en) 1998-05-06 2009-07-15 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
IL141330A0 (en) 1998-08-20 2002-03-10 Regeneron Pharma Dcr5, a bmp-binding protein and aplications thereof
AU6289999A (en) * 1998-10-15 2000-05-01 Zymogenetics Inc. Follistatin-related protein zfsta2
ATE322681T1 (de) 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
WO2001005998A1 (en) 1999-07-16 2001-01-25 Human Genome Sciences, Inc. Follistatin-3
US7098372B1 (en) * 1999-09-13 2006-08-29 Wyeth Pharmaceutical compositions and methods of using secreted frizzled related protein
AU1356401A (en) * 1999-11-03 2001-05-14 Zymogenetics Inc. Follistatin-related protein zfsta4
WO2001064888A2 (en) 2000-02-29 2001-09-07 Zymogenetics, Inc. Kunitz domain polypeptide zkun8
ES2278731T3 (es) * 2000-03-03 2007-08-16 Curagen Corporation Proteinas denominadas fctrx y acidos nucleicos que las codifican.
CA2405709A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003072715A2 (en) 2002-02-21 2003-09-04 Wyeth Gasp1: a follistatin domain containing protein
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
WO2004024092A2 (en) 2002-09-16 2004-03-25 Wyeth Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2004058988A2 (en) 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
CA2601667A1 (en) * 2005-03-23 2006-09-28 Wyeth Detection of gdf-8 modulating agents
JP2008537777A (ja) * 2005-03-23 2008-09-25 ワイス Ｇｄｆ−８調節剤に対する免疫応答の検出

Also Published As

Publication number Publication date
WO2003072714A2 (en) 2003-09-04
KR20040096592A (ko) 2004-11-16
US20030180306A1 (en) 2003-09-25
US20100047259A1 (en) 2010-02-25
US7572763B2 (en) 2009-08-11
EP1572934A4 (en) 2007-12-19
NO20043564L (no) 2004-11-03
AU2003216345A1 (en) 2003-09-09
PL374966A1 (en) 2005-11-14
JP2005531505A (ja) 2005-10-20
US20110020372A1 (en) 2011-01-27
JP2009286804A (ja) 2009-12-10
JP4429728B2 (ja) 2010-03-10
WO2003072714A3 (en) 2006-12-28
CA2476654A1 (en) 2003-09-04
EP1572934A2 (en) 2005-09-14
MXPA04008149A (es) 2005-06-17

Similar Documents

Publication Publication Date Title
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
WO2003072715A8 (en) Gasp1: a follistatin domain containing protein
BR0212809A (pt) Inibidores de anticorpos de gdf-8 e usos dos mesmos
BR0315598A (pt) Anticorpos neutralizantes contra gdf-8 e usos dos mesmos
BR9814984A (pt) Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
BRPI0611965A2 (pt) modulação sinergìstica de cinase flt3 usando um inibidor de flt3 e um inibidor de farnesil transferase
BRPI0409678A (pt) métodos para identificar um composto, para tratar ou prevenir uma doença ou distúrbio em um humano, para incrementar a função de órgãos, tecidos, ou células excitáveis em um humano e para modular a atividade de um complexo de receptores de citocinas protetor de tecidos em um humano
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BR0108175A (pt) Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BR0112476A (pt) Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
BRPI0413574A (pt) aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
BR0015392A (pt) Lipoxina a4 e seus análogos para o tratamento de olho ressecado
BRPI0411020A (pt) perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
BR0207749A (pt) Bactérias do ácido láctico como agentes para tratar e prevenir alergias

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2077 DE 26/10/2010. TEXTO CORRETO: REFERENTE A 7A E 8A ANUIDADES.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.10 PUBLICADO NA RPI 2085 DE 21/12/2009. TEXTO CORRETO: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2077 DE 26/10/2010 E RPI 2085 DE 21/12/2010.